Pfizer's innovative targeted therapy drug Taizena has been approved in China
白云追月素
发表于 2 小时前
120
0
0
The reporter learned that Pfizer's innovative drug for treating prostate cancer, Terzena& reg; (TALZENNA®, The generic name: Terazopanib Tosylate Capsules was approved by the National Medical Products Administration (NMPA) on October 29, 2024, in combination with enzalutamide for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult patients with HRR gene mutations. As the only PARP inhibitor approved for mCRPC treatment of HRR gene mutations in China, Taizena& reg; It will help China achieve breakthroughs in precision diagnosis and treatment of prostate cancer, benefiting Chinese prostate cancer patients. (21st Century Business Herald)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- General Motors Q3 sold over 420000 vehicles in China, surpassing gasoline powered vehicles for the first time in new energy vehicles
- The first weekly long-acting hemophilia therapy has been approved by the FDA from Pfizer
- Has the 'fixed price' policy been effective? General Motors' sales in China increased by 14.3% month on month in the third quarter, and SAIC GM's orders for certain models were overstocked
- Hyatt Hotels and China Resources Land establish a joint venture for light asset expansion, continuing to expand into the Chinese market
- The Boston Science Harbor Base has been completed and opened, achieving "independent production" in China
- When will Apple AI be launched in China? Cook responds!
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Dialogue with Meng Pu, Chairman of Qualcomm China: Qualcomm has long-term accumulation in China and will adhere to the path of self-developed chips
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- This US funded enterprise has clarified its confidence and direction for development in China through the CIIE
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 昨天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 2 小时前
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 4 小时前
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 5 小时前
- 支持
- 反对
- 回复
- 收藏